Core Viewpoint - The high-pressure oxygen chamber concept has seen a significant increase of 7.01%, ranking second among concept sectors, with notable stocks experiencing substantial gains, including a 30% surge for Beiyikang and limit-up performances for International Medicine and Innovative Medical [1][2]. Group 1: Market Performance - The high-pressure oxygen chamber sector had 10 stocks rising, with Beiyikang leading at a 30% increase, followed by International Medicine at 15.18% and Innovative Medical at 5.25% [1]. - The sector attracted a net inflow of 389 million yuan from main funds, with Innovative Medical receiving the highest net inflow of 256 million yuan [2][3]. Group 2: Fund Flow Analysis - The top three stocks in terms of net inflow ratio were Innovative Medical at 74.84%, International Medicine at 41.60%, and Yingkang Life at 8.97% [3]. - The trading performance of key stocks included Innovative Medical with a 10% increase and a turnover rate of 3.48%, while International Medicine rose by 10.02% with a turnover rate of 2.62% [3].

Group 1 - The high-pressure oxygen chamber concept has seen a significant increase of 7.01%, ranking second among concept sectors, with 10 stocks rising, including BeiYikang which hit a 30% limit up, and others like International Medicine and Innovation Medical also reaching their limit up [1] - The main inflow of funds into the high-pressure oxygen chamber concept amounted to 389 million yuan, with Innovation Medical receiving the highest net inflow of 256 million yuan, followed by International Medicine and Yingkang Life [2][3] - The net inflow ratios for major stocks in the high-pressure oxygen chamber concept are led by Innovation Medical at 74.84%, International Medicine at 41.60%, and Yingkang Life at 8.97% [3] Group 2 - The top-performing concept sectors today include Brain-Computer Interface with a rise of 13.70%, while the Free Trade Zone saw a decline of 2.93% [2] - Other notable sectors include Blood Oxygen Meters up 5.65% and 2025 Annual Report Pre-Increase up 5.16% [2] - The trading volume and turnover rates for stocks in the high-pressure oxygen chamber concept indicate active trading, with Innovation Medical showing a turnover rate of 3.48% [3]

三星医疗关于2026年度预计日常关联交易的公告显示，2026年预计关联交易总额不超过22,000万元，涵 盖采购商品、销售商品、提供服务、接受服务及租赁等事项。关联方包括奥克斯集团有限公司及其下属 公司、宁波三星科技有限公司及其下属公司、宁波奥克斯开云医疗投资合伙企业及其下属公司、曙一物 业服务有限公司及其下属公司等。交易价格以市场价格为基础协商确定，不影响公司独立性，亦不构成 对关联方的依赖。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：2026年度预计日常关联交易总额不超过22,000万元。 公司公告汇总：关联交易涉及采购、销售、服务及租赁，定价以市场价为基础。 公司公告汇总：第六届董事会第二十七次会议审议通过关联交易议案，关联董事回避表决。 截至2025年12月26日收盘，三星医疗（601567）报收于22.88元，较上周的23.49元下跌2.6%。本周，三 星医疗12月22日盘中最高价报23.63元。12月26日盘中最低价报22.84元。三星医疗当前最新总市值 323.48亿元，在电网设备板块市值排名9/1 ...

Group 1 - The core viewpoint of the news is that Samsung Medical's stock has experienced a decline, with a current price of 22.69 yuan per share and a market capitalization of 31.884 billion yuan [1] - Samsung Medical, established on February 1, 2007, and listed on June 15, 2011, is primarily engaged in the research, production, and sales of electric energy metering and information collection products, as well as distribution equipment and medical services [1] - The revenue composition of Samsung Medical shows that the electric power segment accounts for 79.70% of total revenue, medical services contribute 19.15%, and other business revenues make up 1.15% [1] Group 2 - From the perspective of fund holdings, one fund under Southern Fund has a significant position in Samsung Medical, specifically the Southern New Energy Industry Trend Mixed A fund, which holds 1.8714 million shares, unchanged from the previous period, representing 5.41% of the fund's net value [2] - The Southern New Energy Industry Trend Mixed A fund has a total scale of 733 million yuan and has achieved a year-to-date return of 22.99%, ranking 4024 out of 8085 in its category [2] - The fund manager, Xiong Lin, has been in position for 4 years and 130 days, with the best and worst fund returns during this period being -22.72% and -24.71%, respectively [3]

Core Viewpoint - The announcement details the expected daily related transactions for the year 2026 by Ningbo SANSING Medical Electric Co., Ltd, indicating that these transactions are necessary for the company's operations and will not adversely affect its independence or financial health [2][14]. Group 1: Daily Related Transactions Overview - The daily related transactions for 2026 do not require shareholder meeting approval [2]. - The expected amount for daily related transactions in 2026 is capped at 220 million yuan [5]. - The board of directors approved the proposal for these transactions during a meeting held on December 30, 2025, with related directors abstaining from voting [3][17]. Group 2: Related Parties and Relationships - The main related party is AUX Group Co., Ltd, which is the controlling shareholder of the company [5][6]. - Other related parties include Ningbo SANSING Technology Co., Ltd and Ningbo AUX Kaiyun Medical Investment Partnership, which are also linked to the company's operations [8][9]. - The financial health of these related parties is stable, indicating a good capacity to fulfill their obligations [12]. Group 3: Transaction Details and Pricing Policy - The daily related transactions include procurement and sales of goods, property services, medical services, and leasing of facilities [12]. - Pricing for these transactions is based on fair market value, ensuring fairness and transparency [13]. Group 4: Impact on the Company - The transactions are aimed at optimizing resource allocation and improving operational efficiency without compromising the company's independence [14]. - The company asserts that these transactions will not negatively impact its financial status or operational results, nor will they harm the interests of minority shareholders [14].

Group 1 - The core point of the article is that Samsung Medical has announced the approval of a proposal regarding expected daily related transactions for the year 2026 during its board meeting [2] - The proposal was passed with the recusal of related directors Shen Guoying, Zheng Jianjiang, and Lv Meng from the voting process [2] - The proposal has also been approved by a special meeting of independent directors [2]

Group 1 - Samsung Medical announced the convening of its 27th meeting of the 6th Board of Directors on December 30, 2025, held both in-person and via communication [1] - The meeting reviewed the proposal regarding the expected daily related transactions for the year 2026 [1]

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-099 宁波三星医疗电气股份有限公司 关于 2026 年度预计日常关联交易的公告 （一）日常关联交易履行的审议程序 宁波三星医疗电气股份有限公司（以下简称"公司"）于2025年12月30日召开公 司第六届董事会第二十七次会议，审议通过了《关于2026年度预计日常关联交易的 议案》，其中关联董事已回避表决，该议案已经独立董事专门会议审议通过。 （二）2025年度日常关联交易的执行情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 2026年度日常关联交易无需提交股东大会审议。 ● 关联交易完成后对上市公司的影响：2026年预计发生的日常关联交易系与公 司日常经营相关的关联交易，符合公司生产经营的实际需求。交易价格以市场价格 为基础协商定价，公平合理，对本公司持续经营能力、盈利能力及资产独立性等不 会产生不利影响。此交易不会影响本公司的独立性，公司主要业务不会因此对关联 方形成依赖。 单位：万元 | | | | | 预计金额 | | | -- ...

该议案已经公司独立董事专门会议审议通过。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 12 月 25 日以电话、传真、邮件等方式发出召开第六届董事会第二十七次会议的通知，会 议于 2025 年 12 月 30 日在公司会议室以现场及通讯方式召开。会议应到董事 9 人，实到董事 9 人，会议由董事长沈国英女士主持，公司其他高级管理人员列席 了会议，会议的召集和召开符合《公司法》和《公司章程》的有关规定。经与会 董事认真审议并表决，通过了以下议案，形成决议如下： 一、审议通过了关于 2026 年度预计日常关联交易的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗关于 2026 年度预计日常关联交易的公告》（公告编号：临 2025-099）。 表决结果：6 票赞成、0 票反对、0 票弃权，3 票回避，关联董事沈国英、郑 坚江、吕萌回避表决。 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-098 宁波三星医疗电气股份有限公司 第六届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏 ...

证券代码：601567 证券简称：三星医疗 公告编号：临2025-097 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 975,350.00 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 80.73% | | 100% 特别风险提示（如有请勾选） | □对外担保总额超过最近一期经审计净资产 担保金额超过上市公司最近一期经审计净 | | 资产 | 50% | | | □对合并报表外单位担保金额达到或超过最 | | | 近一期经审计净资产 30%的情况下 | | | 对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） 无 | | 注：表中截至本公告日上市公司及其控股子公司对外担保总额，包含年度已批准的担 保额度内尚未使用额度与担保实际发生余额之和，并非公 ...